Q-omics provides the consensus-scored ASAH1 profile across patient tissues and cancer cell-line models. ASAH1 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ASAH1 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, ASAH1 protein abundance shows 20,286 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, THCA, and LSCC as cancer lineages where ASAH1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ASAH1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ASAH1 survival associations across molecular data types. ASAH1 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ASAH1 RNA expression–survival associations across cancer types. High ASAH1 expression shows unfavorable associations in GBM, but favorable associations in KIRC, HNSC, COAD, SARC and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ASAH1 RNA expression.
This table summarizes ASAH1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ASAH1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ASAH1 shows lower tumor expression in THCA, LUAD, LUSC, HNSC, KICH and KIRC. The THCA box plot shows higher ASAH1 RNA expression in normal versus tumor tissue (log2 FC = −1.207, t-test p < 0.001).
This table shows molecular features associated with ASAH1 in patient tissues and cancer cell lines. In patient samples, ASAH1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ASAH1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SKIN.
